TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06387511

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrition supplements (SQ-LNS) NutriVax
Description: 1. The SQ-LNS distribution program will be implemented for 12 consecutive months in the NutriVax arm.~2. Community mobilizers in the NutriVax arm will give information in the community about SQ-LNS and eligibility criteria for SQ-LNS distributions.~3. All SQ-LNS distributions will take place at the primary health care center (PHCC) of each ward.~4. Children aged 6-22m, residing in settlements of the catchment area of the NutriVax arm are eligible for a monthly ration of SQ-LNS (28 sachets per month) following a check and update of his or her vaccine status at PHCC; unless there are serious issues related to access to PHCC, in which cases ration sizes may be revised upwards to three months' worth.~5. All children will exit the SQ-LNS distribution program when they are 23 months of age OR after receiving a maximum of 12 consecutive monthly rations, whichever comes first.~6. The total amount of SQ-LNS a child receives will depend on when they enroll in the SQ-LNS distribution program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensitization on vaccination and on Infant and Young Child Feeding (IYCF) practices
Description: 1. Parents or guardian of children will be encouraged/sensitised to attend their scheduled preventive visits to receive other essential paediatric services;~2. Sensitization on vaccination and recommended Infant and Young Child Feeding (IYCF) practices including the need to consume a diverse nutritious diet and support for continued breastfeeding will be conducted according to the Ministry of Health's routine plans in the community and at primary health care centres;~3. Community mobilizers will promote the importance of vaccinations according to the Expanded Program on Immunization (EPI) as well as IYCF good practices messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensitization on vaccination and on Infant and Young Child Feeding (IYCF) practices
Description: 1. Parents or guardian of children will be encouraged/sensitised to attend their scheduled preventive visits to receive other essential paediatric services;~2. Sensitization on vaccination and recommended Infant and Young Child Feeding (IYCF) practices including the need to consume a diverse nutritious diet and support for continued breastfeeding will be conducted according to the Ministry of Health's routine plans in the community and at primary health care centres;~3. Community mobilizers will promote the importance of vaccinations according to the Expanded Program on Immunization (EPI) as well as IYCF good practices messages.
Study: NCT05054036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MoviPrep
Description: Split-dose MoviPrep bowel preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely
Description: Split-dose GoLYTELY bowel preparation
Study: NCT04758078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Description: Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulized 0.9% saline will be given four times per day
Study: NCT05152563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8
Study: NCT05575440

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo a PET/CT scan

Intervention type: RADIATION
Intervention: Fluorine F 18 Tetrafluoroborate
Description: Given IV

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo a PET/CT scan

Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05152563

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study: NCT05821673

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Argon plasma pre-treated abutment insertion
Description: abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Argon plasma pre-treated abutment insertion
Description: abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon plasma pre-treated abutment insertion
Description: abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: abutment insertion
Description: the abutments assigned to the control group were screwed onto the implants without receiving argon plasma pretreatment

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: abutment insertion
Description: the abutments assigned to the control group were screwed onto the implants without receiving argon plasma pretreatment

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: abutment insertion
Description: the abutments assigned to the control group were screwed onto the implants without receiving argon plasma pretreatment
Study: NCT05998668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genital hygiene training
Description: In the first meeting with the women, 2 sessions of 45 minutes with a 10-minute break were held in the counselling rooms of the relevant family health centers. Two weeks after these sessions, a 45-minute session was held in order to reinforce the training with the same method.
Study: NCT05136131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion
Description: Shocks are delivered as per the Ottawa Cardioversion Protocol in the shock arm. 1) 200J shock delivered using self-adhesive electrodes in an anteroposterior configuration. 2) 200J shock delivered using self-adhesive electrodes in an anterolateral configuration while applying pressure over the electrodes with disconnected standard handheld paddles. 3) 360J shock delivered using the same technique as in (2). 4) As per the treating physician's discretion.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electrical cardioversion
Description: No shock is delivered in the sham procedure arm.
Study: NCT06412575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: JNT Guided OGT-overlap Oesophagojejunostomy
Description: In the JNT group, the Joint Nasogastric Tube (JNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TNT Guided OGT-overlap Oesophagojejunostomy
Description: In the TNT group, the Traditional Decompression Nasogastric Tube (TNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
Study: NCT05258630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Homeless Medication Support (D-Homes)
Description: There will be 10 sessions offered within 12 weeks to participants. Sessions will last approximately 30 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide a tailored tool to the patient's needs/goals and tailored diabetes education as needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced usual care
Description: Trained diabetes wellness coaches will provide an approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will read these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Trained diabetes wellness coaches will provide an approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will read these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
Study: NCT04736862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous non-invasive blood pressure monitoring
Description: In patients randomized to the continuous monitoring group, continuous non-invasive finger-cuff blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent non-invasive blood pressure monitoring
Description: In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring using upper-arm cuff oscillometry will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous non-invasive finger-cuff blood pressure monitoring.
Study: NCT05221307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Group 1 will be given MPEs for 45 minutes, 3 days a week for 8 weeks. In the second group, traditional Neurodevelopmental Treatment (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks. Treatments will be carried out by the same physiotherapist. Evaluations will be made twice, before and after the treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: Group 1 will be given MPEs for 45 minutes, 3 days a week for 8 weeks. In the second group, traditional Neurodevelopmental Treatment (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks. Treatments will be carried out by the same physiotherapist. Evaluations will be made twice, before and after the treatment.
Study: NCT06093204

Intervention type: OTHER
Intervention: Dietary evaluation
Description: Comparative evaluation of the dietary consumption of ultraprocessed foods and ultraprocessed foods-derived compounds

Intervention type: OTHER
Intervention: Dietary evaluation
Description: Comparative evaluation of the dietary consumption of ultraprocessed foods and ultraprocessed foods-derived compounds
Study: NCT04433533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of Rosuvastatin 20mg Monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvamibe 10/10
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin10mg/ezetimibe 10mg combination Therapy
Study: NCT03805607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine 30 MG/ML
Description: Ketorolac 30 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal Saline
Study: NCT04656236

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 3-hydroxybutyrate
Description: 3-hydroxybutyrate is a metabolite, produced in the human body.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate
Description: 3-hydroxybutyrate is a metabolite, produced in the human body.
Study: NCT05044000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep propioceptive stimulation
Description: Participants will start using the blanket (of the arm name), 30 days wash-out and 15d with the other blanket

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Deep propioceptive stimulation
Description: Participants will start using the blanket (of the arm name), 30 days wash-out and 15d with the other blanket
Study: NCT06488313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-810
Description: ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).
Study: NCT05191251

Intervention type: DIAGNOSTIC_TEST
Intervention: HEMSTOP questionnaire
Description: A HEMSTOP questionnaire is obtained during the anesthesia consultation.
Study: NCT06266650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Treatment Technique- Muscle Energy Treatment
Description: Muscle Energy Treatment involves a patient actively using their muscles on request from a precisely controlled position, in a specific direction, against a distinctly executed counter force. During Muscle Energy Treatment, the physician positions the area of treatment into a position of resistance, which is the restrictive barrier. The physician then instructs the patient to use the targeted muscles for 3-5 seconds in the direction of ease while the physician provides a counterforce. The physician then tells the patient to stop contracting their muscles and evaluate the area for decreased tension, then repositions the patient into their new restrictive barrier. These steps are repeated three to five times and then the dysfunction is reevaluated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Treatment Technique- Muscle Energy Treatment
Description: Muscle Energy Treatment involves a patient actively using their muscles on request from a precisely controlled position, in a specific direction, against a distinctly executed counter force. During Muscle Energy Treatment, the physician positions the area of treatment into a position of resistance, which is the restrictive barrier. The physician then instructs the patient to use the targeted muscles for 3-5 seconds in the direction of ease while the physician provides a counterforce. The physician then tells the patient to stop contracting their muscles and evaluate the area for decreased tension, then repositions the patient into their new restrictive barrier. These steps are repeated three to five times and then the dysfunction is reevaluated.
Study: NCT05248035

Intervention type: OTHER
Intervention: Adult patient hospitalized in ICU
Description: acquisition of dynamic parameters in addition to pupillary diameter, such as . pupillary diameter, variation of the pupillary diameter, pupillary constriction speed, pupillary dilatation speed, photomotor reflex latency, NPi and symmetry of pupillary responses after a standardized light stimulus
Study: NCT05553041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclovine PET-MRI
Description: 18F-Fluciclovine will be injected via IV prior to Positron emission tomography (PET)-Magnetic resonance imaging (MRI)
Study: NCT06545786

Intervention type: DEVICE
Intervention: Intraoperative electroencephalography
Description: EEG recording will be performed using the standard 16-electrode configuration according to the international 10-20 system. During the recording, electrode impedances will be maintained at a level not exceeding 5 kilo-ohms.
Study: NCT05764824

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry powder
Description: 20 g per day of blueberry powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Controlled and matched powder
Description: 20 g per day
Study: NCT06020417

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O-ARM (Medtronic, Inc, Louisville, CO)
Description: scanner that allows imaging of screws intraoperatively

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional corrective surgery for arthrodesis
Description: Conventional procedure without neuronavigation guide
Study: NCT06644014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participant will communicate with a chatbot-like proprietary AI to receive exercise instructions. The AI will provide personalized advice according to the user's needs, aiming for 2-3 hours of steady-state zone 2 -effort aerobic exercise. Instructions will also be tailored to the user's exercise preferences and limitations (for example, suggest cycling, if running is not convenient).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Supervised HIIT -cycling twice a week. Intensities for cycling intervals will are based on the participants fitness-level determined at first visit. Intensity will gradually increase over the 12-week period

Intervention type: DEVICE
Group type: OTHER
Intervention: Smart Ring
Description: Participants will only receive an Oura Ring, but will not change anything about their normal physical activity.
Study: NCT05328505

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided Radiotherapy
Description: de-escalation radiotherapy to elective volumes + simultaneous integrated boost to PSMA avid lesions delivered in 20 fractions +/- ADT (clinical decision). The elective prostate bed and pelvic lymph node regions will receive 45 Gy. The PSMA-avid lymph node(s) will receive an SIB to 55-60 Gy and/or the PSMA-avid lesion in the prostate bed will receive an SIB to 60 Gy. Pelvic nodal treatment and ADT use will be left to the discretion of the treating physician.
Study: NCT06632093

Intervention type: PROCEDURE
Intervention: hepatic artery infusion chemotherapy
Description: Hepatic arterial infusion chemotherapy including FOLFOX and RALOX

Intervention type: DRUG
Intervention: Lenvatinib + PD-1 monoclonal antibody
Description: PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
Study: NCT06629402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614
Description: Experimental oxycodone prodrug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614
Description: Experimental oxycodone prodrug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive medication
Study: NCT06629597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL201
Description: YL201 will be administered intravenously on Day 1 of each 3-week cycle at RP3D dose level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered intravenously at 75 mg/m2 on Day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered orally at 1000 mg/m2 twice a day (BID) on Days 1 to 14 of each 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at 1000 mg/m2 on Day 1 and 8 of each 3-week cycle
Study: NCT05403138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Induction Phase: (8mg/kg) via intravenous (IV) evey 2 weeks for two cycles. Maintenance Phase: (4mg/kg) IV every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Induction Phase: matching placebo (8mg/kg) via intravenous (IV) every 2 weeks for two cycles; Maintenance Phase: matching placebo (4mg/kg) IV every 4 weeks.
Study: NCT04515797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir and Pibrentasvir
Description: 4 weeks of treatment starting within 24 hrs of kidney transplant
Study: NCT06511934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainGate Neural Interface System
Description: Placement of the BrainGate2 sensor(s) into arm-hand motor-related cortex.
Study: NCT05633771

Intervention type: OTHER
Intervention: Hyrimoz
Description: There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.
Study: NCT06377982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUCB
Description: hUCB
Study: NCT06456554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix (Cortiva Tissue Matrix)
Description: non-crosslinked dermis
Study: NCT05006690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pilates-Based Exercise Training
Description: Clinical Pilates-Based exercise training based on spinal stabilization aim at controlling the position of the trunk over the pelvis to provide optimal energy production and energy transfer to distal segments and involve the cocontraction of muscles, which may restore stability to the spine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pilates-Based Exercise Training
Description: Clinical Pilates-Based exercise training based on spinal stabilization aim at controlling the position of the trunk over the pelvis to provide optimal energy production and energy transfer to distal segments and involve the cocontraction of muscles, which may restore stability to the spine.
Study: NCT06345443

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside Malate
Description: Active supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside Malate
Description: Active supplement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo